-

Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of Teladoc Health, Inc. (TDOC) Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC). The investigation concerns whether Teladoc has violated the federal securities laws and/or engaged in other unlawful business practices.

Teladoc is a global provider of virtual care, transforming the access, cost, and quality dynamics of health care delivery.

On April 27, 2022 Teladoc reported financial results for the three months ended March 31, 2022. Additionally, Teladoc lowered revenue guidance for the balance of the year. The Company had previously told the market at its analyst day in November 2021 that its revenues would grow by 28% year over year in 2022. Then, in February 2022, Teladoc again revised guidance upwards. On this news, the price of Teladoc shares declined by $22.48 per share, or approximately 40.15%, from $55.99 per share to close at $33.51 per share on April 28, 2022.

If you purchased or otherwise acquired Teladoc securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NYSE:TDOC

Release Versions

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

INVESTOR ALERT: Kirby McInerney LLP Files A Securities Class Action Lawsuit Against Camping World Holdings, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that it has filed a class action, Siverd v. Camping World Holdings, Inc. et al., No. 26 Civ. 2710, in the United States District Court for the Northern District of Illinois on behalf of investors who acquired Camping World Holdings, Inc. (“Camping World” or the “Company”) (NYSE:CWH) securities during the period of April 29, 2025 through February 24, 2026, inclusive (“the Class Period”). If you suffered a loss on your Campi...

BYND DEADLINE NOTICE: Beyond Meat, Inc. Investors Encouraged to Contact Kirby McInerney LLP By March 24, 2026

NEW YORK--(BUSINESS WIRE)--If you suffered a loss on your investment in Beyond Meat, Inc. (“Beyond Meat” or the “Company”) (NASDAQ:BYND), contact Lauren Molinaro by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until March 24, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff o...

REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ:CORT) investors of the April 21, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual i...
Back to Newsroom